Women who have gone through menopause and who have been using a vaginal form of oestrogen therapy do not have a higher risk of cardiovascular disease and cancer than women who have not been using any type of oestrogen.

Among women with an intact uterus, the risks of stroke, invasive breast cancer, colorectal cancer, endometrial cancer and pulmonary embolism/deep vein thrombosis were not significantly different between vaginal oestrogen users and nonusers.

The risks of coronary heart disease, fracture and premature death were lower in users than non-users.

The risks of coronary heart disease, stroke, cancer and pulmonary embolism/deep vein thrombosis for women who had undergone hysterectomies were not significantly different in users of vaginal oestrogen compared to nonusers.

Background

Randomised trials and other studies have shown that women who take oestrogen therapy in the form of a pill may have an increased risk of blood clots, stroke and if the oestrogen is used together with progestogen pills, invasive breast cancer.

Some women take a vaginal form of oestrogen, and it has not been known whether that treatment carries risks similar to the tablet form.

Method

The researchers examined data from participants in the Women's Health Initiative Observational Study who were recruited at 40 U.S. clinical centers and were ages 50 to 79 when they began the study.

Impact

This study, the first to examine potential adverse health effects in users of vaginal oestrogen compared with non-users, suggests that vaginal oestrogen therapy is a safe treatment for genitourinary symptoms such as burning, discomfort, and pain during intercourse associated with menopause.

Source: UCLA Life Sciences